Suspended PHASE1 INTERVENTIONAL 1-arm NCT06355908

IL13Rα2 CAR-T for Patients With r/r Glioma (ENHANCING)

Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma

Sponsor: TCRCure Biopharma Ltd.

Conditions Glioma

Interventions IL13Rα2 CAR-T

Updated 4 times since 2024 Last updated: Jan 16, 2026 Started: Mar 21, 2024 Primary completion: May 1, 2026 Completion: May 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Temporarily suspended for HGRAC filing requirements

This PHASE1 trial investigates Glioma and is currently suspended. TCRCure Biopharma Ltd. leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Suspended PHASE1

Status: Recruiting → Suspended
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TCRCure Biopharma Ltd.
Yang Zhang

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China